What is Leerink Partnrs’ Forecast for SCPH FY2027 Earnings?

scPharmaceuticals Inc. (NASDAQ:SCPH) – Research analysts at Leerink Partnrs cut their FY2027 earnings estimates for scPharmaceuticals in a research report issued to clients and investors on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn $0.20 per share for the year, down from their previous estimate of $0.25. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday, March 20th. Maxim Group reduced their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 20th.

scPharmaceuticals Stock Performance

SCPH stock opened at $3.22 on Friday. The company has a market capitalization of $169.99 million, a P/E ratio of -1.69 and a beta of 0.17. The company has a 50-day simple moving average of $2.60 and a 200 day simple moving average of $3.16. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $5.65. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

Institutional Investors Weigh In On scPharmaceuticals

Several institutional investors have recently bought and sold shares of SCPH. Cubist Systematic Strategies LLC acquired a new stake in scPharmaceuticals in the 1st quarter valued at about $76,000. Apis Capital Advisors LLC lifted its holdings in scPharmaceuticals by 28.2% in the 1st quarter. Apis Capital Advisors LLC now owns 504,947 shares of the company’s stock valued at $1,328,000 after acquiring an additional 110,947 shares during the last quarter. Kingdon Capital Management L.L.C. lifted its holdings in scPharmaceuticals by 25.0% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,000,000 shares of the company’s stock valued at $2,630,000 after acquiring an additional 200,000 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in scPharmaceuticals in the 1st quarter valued at about $2,413,000. Finally, Comerica Bank lifted its holdings in scPharmaceuticals by 22.1% in the 1st quarter. Comerica Bank now owns 38,662 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.